GET DAILY SIGNALSDelcath Systems (DCTH) Delivers Strong Q3 2026 Beat with +71% Revenue Growth
Key Takeaways
- Total revenue reached $35.1 million in the third quarter of 2026, up about 71% year over year and well above the roughly $25.6 million consensus estimate.
- Diluted earnings came in at $0.17 per share, a sharp reversal from the $0.10-per-share loss analysts had expected, with net income of $7.0 million.
- HEPZATO KIT revenue climbed to $32.7 million on strong treatment-volume growth, while CHEMOSAT revenue nearly doubled to $2.4 million.
- Gross margin expanded to 89%, and adjusted EBITDA rose to $11.5 million.
- Management raised full-year 2026 revenue guidance to a range of $115 million to $117 million, up from $104 million to $108 million.
- For more context on this ticker, explore Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
- Discover automated strategies and market ideas by exploring Trending AI Robots.
Earnings Context and Why It Matters
Delcath Systems focuses on interventional oncology with liver-directed cancer treatments. Its U.S. commercial efforts center on HEPZATO KIT, a drug-and-device combination that delivers high-dose chemotherapy directly to the liver, plus CHEMOSAT in Europe. As the company scales its launch from a modest base, quarterly revenue growth, treatment-center activations, and new patient starts carry significant weight alongside the bottom line. This report also holds wider importance because it shows whether Delcath Systems can convert rapid top-line gains into steady operating profitability while supporting a growing clinical pipeline. After several quarters of beating estimates, I was watching closely to see if momentum would hold into the typically softer second half.
Breaking Down the Reported Results
Delcath Systems posted total third-quarter 2026 revenue of $35.1 million, up roughly 71% from $20.6 million a year earlier and ahead of the roughly $25.6 million consensus estimate. HEPZATO KIT revenue increased to $32.7 million from $19.3 million, reflecting about 72% year-over-year treatment-volume growth, while CHEMOSAT revenue rose to $2.4 million from $1.3 million. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
On a GAAP basis, the company recorded net income of $7.0 million, or $0.17 per diluted share, versus $0.8 million, or $0.02 per share, in the prior-year period. Analysts had forecast a loss of about $0.10 per share, so the result represented a notable upside surprise. Gross margin widened to 89% from 87%, and adjusted EBITDA climbed to $11.5 million from $5.3 million. Operating cash flow reached $8.2 million, and the company finished the quarter with $104.3 million in cash and investments and no debt.
Management lifted full-year 2026 revenue guidance to $115 million to $117 million from the previous $104 million to $108 million range and now anticipates at least 41% HEPZATO KIT volume growth for the year. The company also passed its 1,000th U.S. commercial HEPZATO treatment during the quarter and added two treatment centers, including AdventHealth, bringing active centers to 33.
Market Reaction and Investor Sentiment
Shares of Delcath Systems rose sharply after the report, climbing more than 25% in early trading as investors reacted to the revenue beat and the second guidance increase of the year. The positive response reflected not only the top-line strength but also the quality of the result, with profit stemming from core operations rather than interest income or tax items.
Sentiment was not entirely uniform, however. The raised guidance points to a sequential revenue decline in the fourth quarter due to holiday seasonality and a slower pace of new-patient starts. Slower-than-expected treatment-center activations and a modest easing in new patient starts per site stayed topics of discussion, even though the company noted that new patient starts remained above its planning assumption.
Forward Outlook and Key Factors to Monitor
After this earnings release, investors will track whether Delcath Systems can maintain treatment-volume growth while navigating the seasonal softness flagged for the fourth quarter. The updated full-year guidance implies fourth-quarter revenue of roughly $25.8 million to $27.8 million, a clear step-down from the record third quarter, so hitting that range will be a near-term priority.
Commercial expansion remains central. The company ended the quarter with 33 active treatment centers and expects at least 36 by year-end, while the addition of AdventHealth could expand referral volume over time. New patient starts per site, which eased to about 0.6 per month, will serve as an important gauge of underlying demand.
On the cost side, R&D and SG&A expenses continue to rise as the company invests in clinical programs and its commercial footprint, which could lead to uneven quarterly profitability. Longer term, pipeline milestones will matter: a colorectal cancer interim analysis is expected around mid-2027, an IND application for cholangiocarcinoma is planned for early 2027, and an oxaliplatin-based program aims to complete preclinical work by mid-2027.
Exploring Tickeron’s AI Screener for Deeper Insights
In my own research process, I often turn to Tickeron’s AI Screener to quickly filter stocks by technical patterns, fundamentals, and performance metrics. It helps surface comparable names in the oncology space and monitor momentum shifts without manual effort, which proved useful when reviewing Delcath Systems alongside peers after this earnings report.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
DCTH in downward trend: 10-day moving average broke below 50-day moving average on October 06, 2026
The 10-day moving average for DCTH crossed bearishly below the 50-day moving average on October 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
DCTH moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DCTH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
The Aroon Indicator for DCTH entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where DCTH's RSI Indicator exited the oversold zone, 28 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 62 cases where DCTH's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on DCTH as a result. In 76 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for DCTH just turned positive on November 04, 2026. Looking at past instances where DCTH's MACD turned positive, the stock continued to rise in 33 of 39 cases over the following month. The odds of a continued upward trend are 85%.
Following a +3.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where DCTH advanced for three days, in 198 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
DCTH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. DCTH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 61 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 90 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.276) is normal, around the industry mean (4.142). DCTH's P/E Ratio (1493.000) is considerably higher than the industry average of (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (6.757) is also within normal values, averaging (40.124).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement